at Fox Business (Aug 29, 2012)
Rexahn Pharmaceuticals (RNN) says it intends to offer shares of its common stock and warrants in an underwritten public offering. The shares are being offered as units, with no amount given at present. Earlier today the company announced it would be receiving additional funding from Teva Pharmaceutical (TEVA) for the development of its potential tumor treatment RX-3117. Burrill and Maxim Group are acting as joint book-running mangers for the offering.
From other sites